Blood
Articles in this Issue
Palbociclib combined with venetoclax and azacitidine in NUP98-rearranged pediatric AML: A multicenter phase II trial demonstrating durable remission and survival benefit
Abstract Background NUP98-rearranged AML has a dismal prognosis with a 2-year OS of less than 35% with current therapies. The combination of...
Reporting of older subgroups in registration trials of FDA and EMA approvals between 2017 and 2023 for diffuse large B-cell lymphoma: A systematic review
Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is primarily a disease of older adults (OA). The median age at diagnosis is in...
Turboid-based proximity labeling reveals SIRT5 network regulation in Acute Myeloid Leukemia cell lines
Abstract Background The SIRT5 lysine deacylase is a critical regulator of cellular metabolic homeostasis. We and others have shown that a la...
Trends and ARIMA-based forecast of sepsis-related mortality in chronic lymphocytic leukemia (CLL): A u.S. population-based analysis from 1999 to 2030
Abstract Background: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, with a median age at diagnosis of app...
CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison
Abstract Background: BCMA-directed CAR-T therapies and bispecific antibodies (BsAbs) have transformed the treatment landscape for relapsed/r...
Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial
Abstract Introduction For patients (pts) with high-tumor burden follicular lymphoma (FL), chemoimmunotherapy remains the...
A novel CD94-targeting CAR T cell therapy for cytotoxic subtypes of T/NK-cell malignancies
Abstract Introduction: Chimeric antigen receptor (CAR) T cell therapy targeting pan-B-cell antigens has shown unprecedented efficacy in B-ce...
Functional regulatory layers shaping the expression of flow cytometry markers in Acute Myeloid Leukemia
Abstract Introduction: Flow cytometry is a central tool in the diagnosis, classification, and monitoring of acute myeloid leukemia (AML), al...
Daratumumab provides equivalent survival benefits in first-line and second-line treatment of transplant-ineligible multiple myeloma: A computational analysis of Phase 3 trials in first-line and second-line settings.
Abstract Introduction Daratumumab is a human IgGκ monoclonal antibody against CD38, with approvals for transplant-inelig...
Conversion from calcineurin inhibitor to ruxolitinib as GVHD prophylaxis during patients with transplant-associated thrombotic microangiopathy
Abstract Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication of allogeneic hematopoietic stem cell...
Clinical feasibility of peripheral blood–based MRD monitoring using the miselect R AML MRD assay in Acute Myeloid Leukemia
Abstract Background Monitoring measurable residual disease (MRD) is critical for guiding post-remission therapy in acute...
Identification of NAE1-dependent β-catenin neddylation as selective vulnerability in B-cell malignancies
Abstract Background and Significance. In epithelial cells, β-catenin promotes canonical WNT signaling and expression of MYC. Mutations that...
Global gender and geographic disparities in leukemia clinical trials authorship
Abstract Introduction: Authorship not only reflects scientific contribution but also serves as metrics for academic recognition and career a...
Evolving patient-reported value of treatment attributes in follicular lymphoma: Insights from the lymphoma coalition 2024 global patient survey on lymphomas and CLL
Abstract Background Follicular lymphoma (FL) is a chronic, indolent lymphoma, characterized by a typically slow-growing but incurable diseas...
Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma
Abstract Introduction: Mantle cell lymphoma (MCL) is an aggressive and rare form of non-Hodgkin lymphoma, with nearly all patients eventuall...
Survival outcomes of adult patients diagnosed with acute lymphoblastic leukemia in the US between 2000-2020 are associated with their sociodemographic characteristics
Abstract Background: Despite highly successful treatment approach,Acute lymphoblastic leukemia (ALL) still leads to significant number of de...
Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models
Abstract Background Novel quadruplet, bispecific and CAR-T therapies have extended survival in myeloma, nonetheless about 20 % of patients s...
Combination of mitoxantrone hydrochloride liposome with gemcitabine, cisplatin and dexamethasone (MGDP) in patients with relapsed or refractory peripheral T cell lymphoma: A prospective, single-arm, multicenter, Phase I/II study
Abstract Background: Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of mature aggressive T-cell non-Hodgkin's lymphomas...
Modified beac as bridging/lymphodepletion therapy followed by CAR-T and autologous stem cell support in relapsed or refractory DLBCL patients: Insights from safety and efficacy outcomes in 12 patients
Abstract Introduction Relapsed or refractory (r/r) DLBCL remains a clinical challenge after first-line chemoimmunotherapy. Chimeric antigen r...
Azacitidine monotherapy versus combination regimens as post-allogeneic transplantation maintenance in high-risk myeloid malignancies: A retrospective cohort Study
Abstract Introduction: Post-transplant relapse remains the leading cause of failure in high-risk acute myeloid leukemia (AML) and myelodyspl...
CD5-positive lymphoproliferative disorders with atypical phenotypes are associated with inferior overall survival compared to typical-phenotype chronic lymphocytic leukaemia when treated with targeted agents.
Abstract Patients with a CD5-positive (CD5+) lymphoproliferative disorder (LPD) who have disease that is phenotypically atypical for Chronic...
Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)
Abstract Background: Lower-risk myelodysplastic neoplasms (LR-MDS) are a group of clonal bone marrow disorders character...
Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.
Abstract Background Despite the approval of multiple novel therapies and substantial improvements in allogeneic stem cel...
Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial
Abstract Introduction: Dose-attenuated rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-mini-CHOP) is a standard...
Viral mimicry in AML is linked to immune activation but not BCL2 inhibitor sensitivity
Abstract Some cancers trigger a response that resembles a viral infection, called viral mimicry, which can stimulate the immune system. This...